Talimogene Laherparepvec: A groundbreaking viral therapy for late stage melanoma: Difference between revisions
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
<br>By Alex Fazioli<br> | <br>By Alex Fazioli<br> | ||
<br>Talimogene Laherparepvec (T-VEC) is an engineered Herpes simplex virus type 1 designed to specifically target, reproduce, and lyse human tumor cells [1]. T-VEC also produces granulocyte macrophage colony-stimulating factor (GM-CSF) to improve the antitumor immune response within the human body upon the lysis of tumor cells [1]. T-VEC avoids infecting non-cancerous cells by having all copies of two key neurovirulence factor genes deleted RL1 and US12 [2]. The deletion of the US12 gene puts its promoter in close proximity to the US11 increasing its expression which has been shown to increase the ability of T-VEC to replicate within tumour cells [3]. | <br>Talimogene Laherparepvec (T-VEC) is an engineered Herpes simplex virus type 1 designed to specifically target, reproduce, and lyse human tumor cells [[#References|[1]]]. T-VEC also produces granulocyte macrophage colony-stimulating factor (GM-CSF) to improve the antitumor immune response within the human body upon the lysis of tumor cells [[#References|[1]]]. T-VEC avoids infecting non-cancerous cells by having all copies of two key neurovirulence factor genes deleted RL1 and US12 [[#References|[2]]]. The deletion of the US12 gene puts its promoter in close proximity to the US11 increasing its expression which has been shown to increase the ability of T-VEC to replicate within tumour cells [[#References|[3]]]. | ||
<br><b>Double brackets:</b> [[ | <br><b>Double brackets:</b> [[ | ||
Line 48: | Line 48: | ||
==References== | ==References== | ||
<references /> | <references /> | ||
1. Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., ... & Milhem, M. (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of clinical oncology, 33(25), 2780-2788. | |||
2. Pol, J., Kroemer, G., & Galluzzi, L. (2016). First oncolytic virus approved for melanoma immunotherapy. | |||
3. Liu, B. L., Robinson, M., Han, Z., Branston, R. H., English, C., Reay, P., & ... Coffin, R. S. (2003). ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy, 10(4), 292. | |||
<br><br>Authored for BIOL 238 Microbiology, taught by [mailto:slonczewski@kenyon.edu Joan Slonczewski], 2018, [http://www.kenyon.edu/index.xml Kenyon College]. | <br><br>Authored for BIOL 238 Microbiology, taught by [mailto:slonczewski@kenyon.edu Joan Slonczewski], 2018, [http://www.kenyon.edu/index.xml Kenyon College]. |
Revision as of 20:40, 2 April 2018
Introduction
[[Image: http://darwin.bio.uci.edu/~faculty/wagner/hsvimg02.jpg%7Cthumb%7C300px%7Cright%7C Figure 1:
[[http://darwin.bio.uci.edu/~faculty/wagner/hsvimg01z.jpg%7Cthumb%7C300px%7Cright%7C
By Alex Fazioli
Talimogene Laherparepvec (T-VEC) is an engineered Herpes simplex virus type 1 designed to specifically target, reproduce, and lyse human tumor cells [1]. T-VEC also produces granulocyte macrophage colony-stimulating factor (GM-CSF) to improve the antitumor immune response within the human body upon the lysis of tumor cells [1]. T-VEC avoids infecting non-cancerous cells by having all copies of two key neurovirulence factor genes deleted RL1 and US12 [2]. The deletion of the US12 gene puts its promoter in close proximity to the US11 increasing its expression which has been shown to increase the ability of T-VEC to replicate within tumour cells [3].
Double brackets: [[
Filename: PHIL_1181_lores.jpg
Thumbnail status: |thumb|
Pixel size: |300px|
Placement on page: |right|
Legend/credit: Electron micrograph of the Ebola Zaire virus. This was the first photo ever taken of the virus, on 10/13/1976. By Dr. F.A. Murphy, now at U.C. Davis, then at the CDC.
Closed double brackets: ]]
Other examples:
Bold
Italic
Subscript: H2O
Superscript: Fe3+
Introduce the topic of your paper. What is your research question? What experiments have addressed your question? Applications for medicine and/or environment?
Sample citations: [1]
[2]
A citation code consists of a hyperlinked reference within "ref" begin and end codes.
Classification
Baltimore classification: dsDNA
Family: Herpesviridae
Virion: Enveloped
Capsid symmetry: Icosahedral
Replication site: Nucleus and cytoplasm
Section 2
Include some current research, with at least one figure showing data.
Section 3
Include some current research, with at least one figure showing data.
Section 4
Conclusion
References
1. Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., ... & Milhem, M. (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of clinical oncology, 33(25), 2780-2788.
2. Pol, J., Kroemer, G., & Galluzzi, L. (2016). First oncolytic virus approved for melanoma immunotherapy.
3. Liu, B. L., Robinson, M., Han, Z., Branston, R. H., English, C., Reay, P., & ... Coffin, R. S. (2003). ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy, 10(4), 292.
Authored for BIOL 238 Microbiology, taught by Joan Slonczewski, 2018, Kenyon College.